Serum and cerebrospinal fluid pharmacokinetics of intravenous and oral lamivudine in human immunodeficiency virus-infected children

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 12, 1998, Pages 3187-3192

  Mueller, Brigitta U ^a,d   Lewis, Linda L ^a,e   Yuen, Geoffrey J ^b,f   Farley, Maureen ^a,g   Keller, Amy ^b   Church, Joseph A ^c   Goldsmith, Jonathan C ^c,h   Venzon, David J ^a   Rubin, Marc ^b   Pizzo, Philip A ^a,d   Balis, Frank M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GLAXOSMITHKLINE   (United States)

^c CHILDREN S HOSPITAL LOS ANGELES   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^f AGOURON PHARMACEUTICALS INC   (United States)

^g Health Care Financing Administration   (United States)

^h Grifols SA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CHILD; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG UPTAKE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0031760630     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.12.3187     Document Type: Article

References (25)

1. Angel, J. B., E. K. Hussey, S. T. Hall, K. H. Donn, D. M. Morris, J. P. McCormack, J. S. G. Montaner, and J. Ruedy. 1993. Pharmacokinetics of 3TC (GR109714X) administered with and without food to HIV-infected patients. Drug Investig. 6:70-74.
2. Balis, F. M., P. A. Pizzo, K. M. Butler, M. E. Hawkins, P. Brouwers, R. N. Husson, F. Jacobsen, S. M. Blaney, J. Gress, P. Jarosinski, and D. G. Poplack. 1992. Clinical pharmacology of 2′,3′-dideoxyinosine in human immunodeficiency virus-infected children. J. Infect. Dis. 165:99-104.
3. Balis, F. M., P. A. Pizzo, J. Eddy, C. Wilfert, R. McKinney, G. Scott, R. F. Murphy, P. F. Jarosinski, J. Falloon, and D. G. Poplack. 1989. Pharmacokinetics of zidovudine administered intravenously and orally in children with human immunodeficiency virus infection. J. Pediatr. 114:880-884.
4. Blaney, S. M., M. J. Daniel, A. J. Harker, K. Godwin, and F. M. Balis. 1995. Pharmacokinetics of lamivudine and BCH-189 in plasma and cerebrospinal fluid of nonhuman primates. Antimicrob. Agents Chemother 39:2779-2782.
5. Cammack, N., P. Rouse, C. L. Marr, P. J. Reid, R. E. Boehme, J. A. Coates, C. R. Penn, and J. M. Cameron. 1992. Cellular metabolism of (-) enantiomeric 2′-deoxy-3′-thiacytidine. Biochem. Pharmacol. 43:2059-2064.
6. Chadwick, E. G., L. A. Nazareno, T. J. Nieuwenhuis, J. W. Massarella, S. R. de Dennis, K. Williams, and R. Yogev. 1995. Phase I evaluation of zalcitabine administered to human immunodeficiency virus-infected children. J. Infect. Dis. 172:1475-1479.
7. Chen, C. H., and Y. C. Cheng. 1989. Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2′,3′-dideoxycytidine. J. Biol. Chem. 264:11934-11937.
8. Coates, J. A. V., N. Cammack, H. J. Jenkinson, A. J. Jowett, M. I. Jowett, B. A. Pearson, C. A. Penn, P. L. Rouse, K. C. Viner, and J. M. Cameron. 1992. (-)-2′-Deoxy-3′-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob. Agents Chemother. 36:733-739.
9. Collins, J. M., R. W. Klecker, J. A. Kelley, J. S. Roth, C. L. McCully, F. M. Balis, and D. G. Poplack. 1988. Pyrimidine dideoxyribonucleosides: selectivity of penetration into cerebrospinal fluid. J. Pharmacol. Exp. Ther. 245:466-470.
10. Crawford, J. D., M. E. Terry, and G. M. Rourke. 1950. Simplification of drug dosage calculated by application of the surface area principle. Pediatrics 5:783-789.
11. Gibaldi, M., and D. Perrier. 1982. Estimation of areas, p. 445-449. In J. Swarbrick (ed.), Pharmacokinetics. Marcel Dekker, Inc., New York, N.Y.
12. Glaxo Wellcome. Personal communication (Amy Keller).
13. Harker, A. J., G. L. Evans, A. E. Hawley, and D. M. Morris. 1994. High-performance liquid chromatographic assay for 2′-deoxy-3′-thiacytidine in human serum. J. Chromatogr. Biomed. Appl. 657:227-232.
14. Hart, G. J., D. C. Orr, C. R. Penn, H. T. Figueiredo, N. M. Gray, R. E. Boehme, and J. M. Cameron. 1992. Effects of (-)-2′-deoxy-3′-thiacytidine 5′-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma. Antimicrob. Agents Chemother. 36:1688-1694.
15. Heald, A. E., P. H. Hsyu, G. J. Yuen, P. Robinson, P. Mydlow, and J. A. Bartlett. 1996. Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Antimicrob. Agents Chemother. 40:1514-1519.
16. Knott, G. D. 1979. MLAB - a mathematical modeling tool. Comput. Programs Biomed. 10:261-280.
17. Lewis, L. L., D. Venzon, J. Church, M. Farley, S. Wheeler, A. Keller, M. Rubin, G. Yuen, B. Mueller, S. Sloas, L. Wood, F. Balis, G. M. Shearer, E. Brouwers, J. Goldsmith, P. A. Pizzo, and NCI Pediatric Branch HIV Working Group. 1996. Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. J. Infect. Dis. 174:16-25.
18. Moore, K. H. P., G. J. Yuen, R. H. Raasch, J. J. Eron, D. Martin, P. K. Mydlow, and E. K. Hussey. 1996. Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole. Clin. Pharmacol. Ther. 59:550-558.
19. Pizzo, P. A., K. Butler, F. Balis, E. Brouwers, M. Hawkins, J. Eddy, M. Einloth, J. Falloon, R. Husson, P. Jarosinski, J. Meer, H. Moss, D. G. Poplack, S. Santacroce, L. Wiener, and P. Wolters. 1990. Dideoxycytidine alone and in an alternating schedule with zidovudine in children with symptomatic human immunodeficiency virus infection. J. Pediatr. 117:799-808.
20. Pluda, J. M., T. P. Cooley, J. S. G. Montaner, L. E. Shay, N. E. Reinhalter, S. N. Warthan, J. Ruedy, H. M. Hirst, C. A. Vicary, J. B. Quinn, G. J. Yuen, M. A. Wainberg, M. Rubin, and R. Yarchoan. 1995. A phase I/II study of 2′-deoxy-3′-thiacytidine in patients with advanced human immunodeficiency virus infection. J. Infect. Dis. 171:1438-1447.
21. Ratain, M. J., and N. J. Vogelzang. 1987. Limited sampling model for vinblastine pharmacokinetics. Cancer Treat. Rep. 71:935-939.
22. Sommadossi, J. P., R. F. Schinazi, C. K. Chu, and M. Y. Xie. 1992. Comparison of cytotoxicity of the (-)-and (+)-enantiomer of 2′,3′-dideoxy-3′-thiacytidine in normal human bone marrow progenitor cells. Biochem. Pharmacol. 44:1921-1925.
23. Soudeyns, H., X. I. Yao, Q. Gao, B. Belleau, J. L. Kraus, N. Nguyen-Ba, B. Spira, and M. A. Wainberg. 1991. Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2′-deoxy-3′-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog. Antimicrob. Agents Chemother. 35:1386-1390.
24. van Leeuwen, R., J. M. A. Lange, E. K. Hussey, K. H. Donn, S. T. Hall, A. J. Harker, P. Jonker, and S. A. Danner. 1992. The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study. AIDS 6:1471-1475.
25. Yuen, G. J., D. M. Morris, P. K. Mydlow, S. Haidar, S. T. Hall, and E. K. Hussey. 1995. Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine. J. Clin. Pharmacol. 35:1174-1180.